{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:23:13Z","timestamp":1793467393000,"version":"4.5.0"},"reference-count":244,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Glutamate is the brain\u2019s main excitatory neurotransmitter. Glutamatergic neurons primarily compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and inhibitory activities may result in epilepsy or other neurological and psychiatric conditions. Among glutamate receptors, AMPA receptors are the predominant mediator of glutamate-induced excitatory neurotransmission and dictate synaptic efficiency and plasticity by their numbers and\/or properties. Therefore, they appear to be a major drug target for modulating several brain functions. Perampanel (PER) is a highly selective, noncompetitive AMPA antagonist approved in several countries worldwide for treating different types of seizures in various epileptic conditions. However, recent data show that PER can potentially address many other conditions within epilepsy and beyond. From this perspective, this review aims to examine the new preclinical and clinical studies\u2014especially those produced from 2017 onwards\u2014on AMPA antagonism and PER in conditions such as mesial temporal lobe epilepsy, idiopathic and genetic generalized epilepsy, brain tumor-related epilepsy, status epilepticus, rare epileptic syndromes, stroke, sleep, epilepsy-related migraine, cognitive impairment, autism, dementia, and other neurodegenerative diseases, as well as provide suggestions on future research agenda aimed at probing the possibility of treating these conditions with PER and\/or other AMPA receptor antagonists.<\/jats:p>","DOI":"10.3389\/fneur.2023.1182304","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T19:22:00Z","timestamp":1688671320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy"],"prefix":"10.3389","volume":"14","author":[{"given":"Fabio","family":"Perversi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Meletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lino","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Felicia","family":"Operto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8607038","DOI":"10.1155\/2016\/8607038","article-title":"Plasticity of hippocampal excitatory-inhibitory balance: missing the synaptic control in the epileptic brain","volume":"2016","author":"Bonansco","year":"2016","journal-title":"Neural Plast"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"797253","DOI":"10.3389\/fnmol.2021.797253","article-title":"Roles of N-methyl-D-aspartate receptors (NMDARs) in epilepsy","volume":"14","author":"Chen","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"108569","DOI":"10.1016\/j.neuropharm.2021.108569","article-title":"Kainate and AMPA receptors in epilepsy: cell biology, signalling pathways and possible crosstalk","volume":"195","author":"Henley","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"652159","DOI":"10.3389\/fneur.2021.652159","article-title":"Dysregulation of ambient glutamate and glutamate receptors in epilepsy: an astrocytic perspective","volume":"12","author":"Alcoreza","year":"2021","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14728222.2019.1586885","article-title":"Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status","volume":"23","author":"Celli","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/j.1471-4159.2005.03334.x","article-title":"Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala","volume":"94","author":"Gryder","year":"2005","journal-title":"J Neurochem"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"ref11","year":"2021"},{"key":"ref12","year":"2022"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10072-020-04636-7","article-title":"Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study","volume":"42","author":"Labate","year":"2021","journal-title":"Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"52900","DOI":"10.3389\/fneur.2022.9","article-title":"Perampanel and childhood absence epilepsy: a real life experience","volume":"13","author":"Operto","year":"2022","journal-title":"Front Neurol"},{"key":"ref17","first-page":"1242","article-title":"Perampanel in elderly patients: an overview of data from studies 307, 335, 412, 342, and 506","volume":"98","author":"Leppik","year":"2022","journal-title":"Poster Present Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106655","DOI":"10.1016\/j.yebeh.2019.106655","article-title":"Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON)","volume":"102","author":"Abril Jaramillo","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"106570","DOI":"10.1016\/j.eplepsyres.2021.106570","article-title":"Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study","volume":"172","author":"Rodr\u00edguez-Osorio","year":"2021","journal-title":"Epilepsy Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/epi4.12649","article-title":"Effectiveness of perampanel as the only add-on: retrospective, multicenter, observational real life study on epilepsy patients","volume":"7","author":"Gasparini","year":"2022","journal-title":"Epilepsia Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"ref22","article-title":"Idiopathic (genetic) generalized epilepsy","volume-title":"StatPearls","author":"McWilliam","year":"2022"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.24103","article-title":"Long-term outcome in epilepsy with grand mal on awakening: forty years of follow-up","volume":"75","author":"Holtkamp","year":"2014","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.13556","article-title":"Seizure outcome trajectories in a well-defined cohort of newly diagnosed juvenile myoclonic epilepsy patients","volume":"145","author":"Cerulli Irelli","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref25","year":""},{"key":"ref26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.seizure.2020.06.011","article-title":"Adjunctive perampanel and myoclonic and absence seizures: post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy","volume":"80","author":"Brandt","year":"2020","journal-title":"Seizure"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.seizure.2020.09.026","article-title":"Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs","volume":"83","author":"Santamarina","year":"2020","journal-title":"Seizure"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/epi.17388","article-title":"Perampanel for the treatment of patients with idiopathic generalised epilepsy in clinical practice","volume":"63","author":"Trinka","year":"2022","journal-title":"Oral Present Epilep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2022.06.008","article-title":"Perampanel for the treatment of patients with myoclonic seizures in clinical practice: evidence from the PERMIT study","volume":"100","author":"D'Souza","year":"2022","journal-title":"Seizure"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrneurol.2010.212","article-title":"Benign mesial temporal lobe epilepsy","volume":"7","author":"Labate","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/jpet.114.212779","article-title":"Perampanel, an antagonist of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models","volume":"351","author":"Zwart","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/epi.13328","article-title":"Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy","volume":"57","author":"Russmann","year":"2016","journal-title":"Epilepsia"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1517\/14656566.2015.1084504","article-title":"Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"16","author":"Palleria","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"116903","DOI":"10.1016\/j.jns.2020.116903","article-title":"The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \"real world\" context: focus on temporal lobe epilepsy","volume":"415","author":"Pascarella","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e17171","DOI":"10.1097\/MD.0000000000017171","article-title":"Effectiveness and safety of perampanel in adults with mesial temporal epilepsy: a single-center postmarketing study in Taiwan","volume":"98","author":"Lin","year":"2019","journal-title":"Medicine"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"100393","DOI":"10.1016\/j.ebr.2020.100393","article-title":"Perampanel as add-on therapy in epilepsies with known etiology: a single center experience with long-term follow-up","volume":"15","author":"Nilo","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11060-014-1449-7","article-title":"Weight of epilepsy in brain tumor patients","volume":"118","author":"Maschio","year":"2014","journal-title":"J Neuro-Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/157015912800604470","article-title":"Brain tumor-related epilepsy","volume":"10","author":"Maschio","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"120584","DOI":"10.1016\/j.jns.2023.120584","article-title":"Epilepsy and brain tumors: two sides of the same coin","volume":"446","author":"Aronica","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/glia.21113","article-title":"Glutamate and the biology of gliomas","volume":"59","author":"de Groot","year":"2011","journal-title":"Glia"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e47846","DOI":"10.1371\/journal.pone.0047846","article-title":"Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells","volume":"7","author":"Oh","year":"2012","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/ijms20071796","article-title":"Glutamate receptors and glioblastoma multiforme: an old \"route\" for new perspectives","volume":"20","author":"Corsi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e0211644","DOI":"10.1371\/journal.pone.0211644","article-title":"AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro","volume":"14","author":"Lange","year":"2019","journal-title":"PLoS One"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/jpm11050390","article-title":"Synergistic effect of perampanel and temozolomide in human glioma cell lines","volume":"11","author":"Salmaggi","year":"2021","journal-title":"J Pers Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3892\/ol.2022.13541","article-title":"Anti-tumor effects of perampanel in malignant glioma cells","volume":"24","author":"Tatsuoka","year":"2022","journal-title":"Oncol Lett"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nm746","article-title":"Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells","volume":"8","author":"Ishiuchi","year":"2002","journal-title":"Nat Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"598266","DOI":"10.3389\/fnins.2020.598266","article-title":"Perampanel add-on to standard radiochemotherapy in vivo promotes neuroprotection in a rodent F98 glioma model","volume":"14","author":"Lange","year":"2020","journal-title":"Front Neurosci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11060-017-2473-1","article-title":"Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations","volume":"133","author":"Vecht","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ebcr.2018.09.003","article-title":"Adjunctive perampanel for glioma-associated epilepsy","volume":"10","author":"Dunn-Pirio","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.21873\/anticanres.12737","article-title":"Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel","volume":"38","author":"Izumoto","year":"2018","journal-title":"Anticancer Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/00207454.2018.1555160","article-title":"Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis","volume":"129","author":"Maschio","year":"2019","journal-title":"Int J Neurosci"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2176\/nmc.oa.2018-0245","article-title":"Experience of low dose perampanel to add-on in glioma patients with levetiracetam-uncontrollable epilepsy","volume":"60","author":"Chonan","year":"2020","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fneur.2020.00592","article-title":"Perampanel confirms to be effective and well-tolerated as an add-on treatment in patients with brain tumor-related epilepsy (PERADET study)","volume":"11","author":"Coppola","year":"2020","journal-title":"Front Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e01612","DOI":"10.1002\/brb3.1612","article-title":"Perampanel in brain tumor-related epilepsy: observational pilot study","volume":"10","author":"Maschio","year":"2020","journal-title":"Brain Behav"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/cells10051226","article-title":"Glutamatergic mechanisms in Glioblastoma and tumor-associated epilepsy","volume":"10","author":"Lange","year":"2021","journal-title":"Cells"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/epi.17388","article-title":"Clinical practice evidence for perampanel in epilepsy patients with tumour aetiology","volume":"63","author":"Coppola","year":"2022","journal-title":"Oral Present Epilep"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","article-title":"Pharmacotherapy for status epilepticus","volume":"75","author":"Trinka","year":"2015","journal-title":"Drugs"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1528-1167.2009.02323.x","article-title":"Refractory status epilepticus: a prospective observational study","volume":"51","author":"Novy","year":"2010","journal-title":"Epilepsia"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","article-title":"Perampanel in the treatment of status epilepticus: a systematic review of the literature","volume":"86","author":"Brigo","year":"2018","journal-title":"Epilepsy Behav"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/epi.14082","article-title":"The role of AMPA receptors and their antagonists in status epilepticus","volume":"59","author":"Leo","year":"2018","journal-title":"Epilepsia"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00381-012-1747-3","article-title":"Expression of AMPA receptor subunits in hippocampus after status convulsion","volume":"28","author":"Hu","year":"2012","journal-title":"Childs Nerv Syst"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.23570","article-title":"Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus","volume":"72","author":"Rajasekaran","year":"2012","journal-title":"Ann Neurol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/(SICI)1098-1063(1998)8:5<511::AID-HIPO9>3.0.CO;2-W","article-title":"Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss","volume":"8","author":"Friedman","year":"1998","journal-title":"Hippocampus"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1073\/pnas.050586497","article-title":"Status epilepticus decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before neuronal death","volume":"97","author":"Grooms","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/1098-2396(20001215)38:4<489::AID-SYN15>3.0.CO;2-N","article-title":"Functional downregulation of GluR2 in piriform cortex of kindled animals","volume":"38","author":"Prince","year":"2000","journal-title":"Synapse"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/epi.14482","article-title":"Mechanisms of status epilepticus: \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor hypothesis","volume":"59","author":"Joshi","year":"2018","journal-title":"Epilepsia"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ana.25635","article-title":"\u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor plasticity sustains severe, fatal status epilepticus","volume":"87","author":"Adotevi","year":"2020","journal-title":"Ann Neurol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"108320","DOI":"10.1016\/j.yebeh.2021.108320","article-title":"Down-regulation of AMPA receptors and long-term potentiation during early epileptogenesis","volume":"124","author":"Cruz Del Angel","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00415-012-6644-x","article-title":"Treatment deviating from guidelines does not influence status epilepticus prognosis","volume":"260","author":"Rossetti","year":"2013","journal-title":"J Neurol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.14492","article-title":"Efficacy and safety of perampanel oral loading in postanoxic super-refractory status epilepticus: a pilot study","volume":"59","author":"Beretta","year":"2018","journal-title":"Epilepsia"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/epi.14494","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12028-019-00704-9","article-title":"Perampanel treatment for refractory status epilepticus in a neurological intensive care unit","volume":"31","author":"Ho","year":"2019","journal-title":"Neurocrit Care"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"117214","DOI":"10.1016\/j.jns.2020.117214","article-title":"A retrospective, observational study of perampanel in refractory and super-refractory status epilepticus","volume":"419","author":"Alsherbini","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.19080\/OAJNN.2020.13.555874","article-title":"Efficacy of immediate perampanel oral loading in convulsive status epilepticus: a single-center experience of consecutive 22 patients","volume":"13","author":"Ishida","year":"2020","journal-title":"Open Access J Neurol Neurosurg"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00415-021-10506-9","article-title":"Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review","volume":"268","author":"Lim","year":"2021","journal-title":"J Neurol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"3218231","DOI":"10.1155\/2019\/3218231","article-title":"Super-refractory status epilepticus treated with high dose perampanel: case series and review of the literature","volume":"2019","author":"Newey","year":"2019","journal-title":"Case Rep Crit Care"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/epi.13981","article-title":"Comparative efficacy of antiepileptic drugs in children and adolescents: a network meta-analysis","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.eplepsyres.2017.11.007","article-title":"Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children","volume":"139","author":"Mohd-Tahir","year":"2018","journal-title":"Epilepsy Res"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"108069","DOI":"10.1016\/j.yebeh.2021.108069","article-title":"Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up","volume":"121","author":"Fernandes","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref96","year":"2019"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/epi4.12575","article-title":"PROVE: retrospective, non-interventional, phase IV study of perampanel in real-world clinical care of patients with epilepsy","volume":"7","author":"Wechsler","year":"2022","journal-title":"Epilepsia Open"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/08830738211047665","article-title":"PROVE-phase IV study of perampanel in real-world clinical care of patients with epilepsy: interim analysis in pediatric patients","volume":"37","author":"Segal","year":"2022","journal-title":"J Child Neurol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1002\/ana.26459","article-title":"Effectiveness, safety and tolerability of perampanel in pediatric and adolescent patients with focal-onset and generalized-onset seizures: evidence from clinical practice. Abstract presentation from the 51st annual meeting of the child neurology society","volume":"92","author":"Auvin","year":"2022","journal-title":"Ann Neurol"},{"key":"ref100","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329195","article-title":"Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy","volume-title":"J Neurol Neurosurg Psychiatry","author":"Matricardi","year":"2022"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/jcm11010267","article-title":"Cognitive impairment in people with epilepsy","volume":"11","author":"Novak","year":"2022","journal-title":"J Clin Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive effects of Antiseizure medications in children and adolescents with epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Paediatr Drugs"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"696946","DOI":"10.3389\/fneur.2021.696946","article-title":"Perampanel and visuospatial skills in children with epilepsy","volume":"12","author":"Operto","year":"2021","journal-title":"Front Neurol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yebeh.2018.03.029","article-title":"Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures","volume":"83","author":"Pi\u00f1a-Garza","year":"2018","journal-title":"Epilepsy Behav"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.eplepsyres.2016.08.025","article-title":"Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures","volume":"127","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures","volume":"61","author":"Fogarasi","year":"2020","journal-title":"Epilepsia"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1212\/WNL.94.15_supplement.351","article-title":"Perampanel exposure-response relationships for cognition and safety in pediatric patients (aged 4 to < 12 years) with epilepsy","volume":"94","author":"Majid","year":"2020","journal-title":"Neurology"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"106879","DOI":"10.1016\/j.yebeh.2019.106879","article-title":"Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions","volume":"103","author":"Operto","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1550059420947936","article-title":"Perampanel increases cortical eeg fast activity in child and adult patients affected by epilepsy: a quantitative EEG study","volume":"52","author":"Liguori","year":"2021","journal-title":"Clin EEG Neurosci"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"107803","DOI":"10.1016\/j.yebeh.2021.107803","article-title":"Perampanel effects on cognition and quantitative EEG in patients with epilepsy","volume":"117","author":"Liguori","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41582-021-00505-9","article-title":"Amyloid-\u03b2: a potential link between epilepsy and cognitive decline","volume":"17","author":"Romoli","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/14656566.2020.1865311","article-title":"Pharmacotherapeutic considerations for late-onset epilepsy","volume":"22","author":"Brigo","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5698\/1535-7597-15.s1.1","article-title":"One-year real-world experience of perampanel in elderly patients with refractory focal epilepsy. AES 2014 annual meeting - online abstract supplement","volume":"15","author":"H\u2019fler","year":"2015","journal-title":"Epilepsy Curr"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40266-021-00865-3","article-title":"Adjunctive perampanel in older patients with epilepsy: a multicenter study of clinical practice","volume":"38","author":"Lattanzi","year":"2021","journal-title":"Drugs Aging"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","article-title":"Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials","volume":"110","author":"Leppik","year":"2015","journal-title":"Epilepsy Res"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/epi.13600","article-title":"Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies","volume":"58","author":"Leppik","year":"2017","journal-title":"Epilepsia"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1126\/science.1162844","article-title":"Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease","volume":"321","author":"Busche","year":"2008","journal-title":"Science"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/nn1503","article-title":"Regulation of NMDA receptor trafficking by amyloid-beta","volume":"8","author":"Snyder","year":"2005","journal-title":"Nat Neurosci"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s0896-6273(03)00124-7","article-title":"APP processing and synaptic function","volume":"37","author":"Kamenetz","year":"2003","journal-title":"Neuron"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.3390\/ijms22115991","article-title":"An unbalanced synaptic transmission: cause or consequence of the amyloid oligomers neurotoxicity?","volume":"22","author":"Sciaccaluga","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1038\/srep10934","article-title":"Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus","volume":"5","author":"Whitcomb","year":"2015","journal-title":"Sci Rep"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neurobiolaging.2019.09.005","article-title":"Co-activation of selective nicotinic acetylcholine receptors is required to reverse beta amyloid-induced Ca2+ hyperexcitation","volume":"84","author":"Sun","year":"2019","journal-title":"Neurobiol Aging"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neurobiolaging.2016.08.025","article-title":"Epilepsy, amyloid-\u03b2, and D1 dopamine receptors: a possible pathogenetic link?","volume":"48","author":"Costa","year":"2016","journal-title":"Neurobiol Aging"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3233\/JAD-170879","article-title":"Amyloid-\u03b2 induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer's disease","volume":"62","author":"Zhang","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"13441","DOI":"10.1038\/ncomms13441","article-title":"Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding A\u03b2 plaques by iGluSnFR two-photon imaging","volume":"7","author":"Hefendehl","year":"2016","journal-title":"Nat Commun"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","article-title":"Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy","volume":"29","author":"Minkeviciene","year":"2009","journal-title":"J Neurosci"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","article-title":"Amyloid deposition is associated with impaired default network function in older persons without dementia","volume":"63","author":"Sperling","year":"2009","journal-title":"Neuron"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat Neurosci"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3233\/JAD-2011-091717","article-title":"Soluble A\u03b2(1-40) peptide increases excitatory neurotransmission and induces epileptiform activity in hippocampal neurons","volume":"23","author":"Cuevas","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nbd.2015.10.019","article-title":"Soluble A\u03b2 oligomers impair hippocampal LTP by disrupting glutamatergic\/GABAergic balance","volume":"85","author":"Lei","year":"2016","journal-title":"Neurobiol Dis"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hipo.23129","article-title":"Single amyloid-beta injection exacerbates 4-aminopyridine-induced seizures and changes synaptic coupling in the hippocampus","volume":"29","author":"Alcantara-Gonzalez","year":"2019","journal-title":"Hippocampus"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","article-title":"A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation","volume":"365","author":"Zott","year":"2019","journal-title":"Science"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nn.2709","article-title":"Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease","volume":"14","author":"D'Amelio","year":"2011","journal-title":"Nat Neurosci"},{"key":"ref139","first-page":"157","article-title":"Seizure susceptibility and mortality in mice that over-express amyloid precursor protein","volume":"1","author":"Westmark","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"20119","DOI":"10.1038\/srep20119","article-title":"Interictal spikes during sleep are an early defect in the Tg2576 mouse model of \u03b2-amyloid neuropathology","volume":"6","author":"Kam","year":"2016","journal-title":"Sci Rep"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1073\/pnas.0600948103","article-title":"Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease","volume":"103","author":"Jacobsen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"109373","DOI":"10.1016\/j.neuropharm.2022.109373","article-title":"Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis","volume":"225","author":"Bellingacci","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"93","DOI":"10.14581\/jer.21012","article-title":"A severe dementia case in end of life care with psychiatric symptoms treated by perampanel","volume":"11","author":"Kumamoto","year":"2021","journal-title":"J Epilepsy Res"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front Neurol"},{"key":"ref146","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17530","article-title":"Perampanel as precision therapy in rare genetic epilepsies","volume-title":"Epilepsia","author":"Nissenkorn","year":"2023"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1212\/WNL.0000000000000077","article-title":"Progressive myoclonic epilepsies: definitive and still undetermined causes","volume":"82","author":"Franceschetti","year":"2014","journal-title":"Neurology"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"106191","DOI":"10.1016\/j.eplepsyres.2019.106191","article-title":"An Italian multicentre study of perampanel in progressive myoclonus epilepsies","volume":"156","author":"Canafoglia","year":"2019","journal-title":"Epilepsy Res"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"630366","DOI":"10.3389\/fneur.2021.630366","article-title":"Perampanel improves cortical myoclonus and disability in progressive myoclonic epilepsies: a case series and a systematic review of the literature","volume":"12","author":"Assenza","year":"2021","journal-title":"Front Neurol"},{"key":"ref150","article-title":"Lennox-Gastaut syndrome","volume-title":"Epileptic Syndromes in Infancy, Childhood and Adolescence","author":"Crespel","year":"2019"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for Lennox-gastaut syndrome: current and future strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"key":"ref153","year":"2022"},{"key":"ref154","first-page":"S157","article-title":"Design and methods of study 338: a multicenter, double-blind, randomized, placebo-controlled trial of perampanel as adjunctive treatment in subjects >=2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndrome","volume":"58","author":"Wechsler","year":"2017","journal-title":"Epilepsia"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1002\/ana.26459","article-title":"Efficacy and safety of perampanel in pediatric patients aged 2-<12 years with seizures associated with Lennox-Gastaut syndrome. Abstract presentation from the 51st annual meeting of the child neurology society","volume":"92","author":"Porter","year":"2022","journal-title":"Ann Neurol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.seizure.2019.12.012","article-title":"Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome","volume":"75","author":"Crespel","year":"2020","journal-title":"Seizure"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Bir\u00f3","year":"2015","journal-title":"Neuropediatrics"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yebeh.2016.10.020","article-title":"A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment","volume":"66","author":"Huber","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/epi.12492","article-title":"First clinical experiences with perampanel\u2014the Kork experience in 74 patients","volume":"55","author":"Steinhoff","year":"2014","journal-title":"Epilepsia"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"108836","DOI":"10.1016\/j.yebeh.2022.108836","article-title":"Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice","volume":"134","author":"Alonso-Singer","year":"2022","journal-title":"Epilepsy Behav"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/epi.17601","article-title":"Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: a multicenter retrospective study","volume":"64","author":"Matricardi","year":"2023","journal-title":"Epilepsia"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"682767","DOI":"10.3389\/fphar.2021.682767","article-title":"Perampanel reduces hyperthermia-induced seizures in Dravet syndrome mouse model","volume":"12","author":"Ho","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eplepsyres.2019.02.014","article-title":"Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome","volume":"154","author":"Yoshitomi","year":"2019","journal-title":"Epilepsy Res"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.seizure.2019.12.024","article-title":"The efficacy of perampanel in young children with drug-resistant epilepsy","volume":"75","author":"Chang","year":"2020","journal-title":"Seizure"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"2329048X211050711","DOI":"10.1177\/2329048X211050711","article-title":"Long-term efficacy of perampanel in a child with Dravet syndrome","volume":"8","author":"Tur\u00f3n-Vi\u00f1as","year":"2021","journal-title":"Child Neurol Open"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2019.05.024","article-title":"Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation","volume":"71","author":"Ishikawa","year":"2019","journal-title":"Seizure"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcdb.2021.02.007","article-title":"The why and how of sleep-dependent synaptic down-selection","volume":"125","author":"Cirelli","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuron.2013.12.025","article-title":"Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration","volume":"81","author":"Tononi","year":"2014","journal-title":"Neuron"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nn2035","article-title":"Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep","volume":"11","author":"Vyazovskiy","year":"2008","journal-title":"Nat Neurosci"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1523\/JNEUROSCI.5486-08.2009","article-title":"Long-term homeostasis of extracellular glutamate in the rat cerebral cortex across sleep and waking states","volume":"29","author":"Dash","year":"2009","journal-title":"J Neurosci"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0166-2236(90)90135-w","article-title":"Brief seizure episodes induce long-term potentiation and mossy fibre sprouting in the hippocampus","volume":"13","author":"Ben-Ari","year":"1990","journal-title":"Trends Neurosci"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s1059-1311(97)80034-9","article-title":"Seizures, memory and synaptic plasticity","volume":"6","author":"Reid","year":"1997","journal-title":"Seizure"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/(SICI)1097-4547(19991001)58:1<42::AID-JNR6>3.0.CO;2-L","article-title":"The plasticity-pathology continuum: defining a role for the LTP phenomenon","volume":"58","author":"McEachern","year":"1999","journal-title":"J Neurosci Res"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1528-1167.2006.00416.x","article-title":"A brief period of epileptiform activity strengthens excitatory synapses in the rat hippocampus in vitro","volume":"47","author":"Debanne","year":"2006","journal-title":"Epilepsia"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1535-7511.2006.00145.x","article-title":"Interictal spikes and epileptogenesis","volume":"6","author":"Staley","year":"2006","journal-title":"Epilepsy Curr"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1528-1167.2007.01396.x","article-title":"The basic science of memory as it applies to epilepsy","volume":"48","author":"Meador","year":"2007","journal-title":"Epilepsia"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/brain\/awx017","article-title":"Altered sleep homeostasis correlates with cognitive impairment in patients with focal epilepsy","volume":"140","author":"Boly","year":"2017","journal-title":"Brain"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1523\/JNEUROSCI.3019-14.2015","article-title":"Evidence for consolidation of neuronal assemblies after seizures in humans","volume":"35","author":"Bower","year":"2015","journal-title":"J Neurosci"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fneur.2020.00398","article-title":"Circadian-like rhythmicity of extracellular brain glutamate in epilepsy","volume":"11","author":"Sandhu","year":"2020","journal-title":"Front Neurol"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1474-4422(18)30274-6","article-title":"Circadian and circaseptan rhythms in human epilepsy: a retrospective cohort study","volume":"7","author":"Karoly","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neubiorev.2019.01.004","article-title":"Chronobiology of limbic seizures: potential mechanisms and prospects of chronotherapy for mesial temporal lobe epilepsy","volume":"98","author":"Leite G\u00f3es Gitai","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"101559","DOI":"10.1016\/j.smrv.2021.101559","article-title":"Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: a literature review","volume":"60","author":"Liguori","year":"2021","journal-title":"Sleep Med Rev"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"108341","DOI":"10.1016\/j.yebeh.2021.108341","article-title":"Expert opinion: managing sleep disturbances in people with epilepsy","volume":"124","author":"Nobili","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.seizure.2008.02.005","article-title":"Influence of sleep disturbance on quality of life of patients with epilepsy","volume":"17","author":"Piperidou","year":"2008","journal-title":"Seizure"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.eplepsyres.2010.05.006","article-title":"Comorbidity between epilepsy and sleep disorders","volume":"90","author":"Manni","year":"2010","journal-title":"Epilepsy Res"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/s1388-2457(00)00411-9","article-title":"Effect of antiepileptic drugs on sleep","volume":"111","author":"Placidi","year":"2000","journal-title":"Clin Neurophysiol"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/epi.12478","article-title":"Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics","volume":"55","author":"Jain","year":"2014","journal-title":"Epilepsia"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yebeh.2016.08.004","article-title":"Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures","volume":"63","author":"Toledo","year":"2016","journal-title":"Epilepsy Behav"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ebcr.2016.10.002","article-title":"Effect of adjunctive perampanel on the quality of sleep and daytime somnolence in patients with epilepsy","volume":"7","author":"Gonz\u00e1lez-Cuevas","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yebeh.2016.10.033","article-title":"Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: further data","volume":"67","author":"Romigi","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"107384","DOI":"10.1016\/j.yebeh.2020.107384","article-title":"Insomnia is less prevalent and less severe, independent of depressive symptoms, in patients with epilepsy treated with perampanel as an adjuvant","volume":"112","author":"Lee","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.seizure.2020.01.021","article-title":"Perampanel effect on sleep architecture in patients with epilepsy","volume":"76","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.seizure.2022.02.011","article-title":"Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: results from the retrospective phase IV PROVE study","volume":"98","author":"Segal","year":"2022","journal-title":"Seizure"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/epi.17388","article-title":"Efficacy of perampanel in nocturnal seizures in adult patients with epilepsy","volume":"63","author":"Maza","year":"2022","journal-title":"Oral Present Epilep"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s10072-022-06536-4","article-title":"Sleep-wake cycle and daytime sleepiness in patients with epilepsy after initiating perampanel as adjunctive therapy","volume":"44","author":"Fernandes","year":"2023","journal-title":"Neurol Sci"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1212\/WNL.0000000000002666","article-title":"Definition and diagnostic criteria of sleep-related hypermotor epilepsy","volume":"86","author":"Tinuper","year":"2016","journal-title":"Neurology"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.sleep.2020.12.020","article-title":"Treatment of pharmacoresistant sleep-related hypermotor epilepsy (SHE) with the selective AMPA receptor antagonist perampanel","volume":"81","author":"Lim","year":"2021","journal-title":"Sleep Med"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.sleep.2017.03.012","article-title":"Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel","volume":"34","author":"Garcia-Borreguero","year":"2017","journal-title":"Sleep Med"},{"key":"ref200","first-page":"112","article-title":"Use of perampanel in treatment-resistant insomnia","volume":"46","author":"G\u00f3mez-Arnau","year":"2018","journal-title":"Actas Esp Psiquiatr"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"105724","DOI":"10.1016\/j.clineuro.2020.105724","article-title":"Perampanel in chronic insomnia","volume":"192","author":"Abenza-Abild\u00faa","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.gendis.2018.04.007","article-title":"Epilepsy and migraine-are they comorbidity?","volume":"5","author":"Liao","year":"2018","journal-title":"Genes Dis"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s10194-015-0556-y","article-title":"Headache in epilepsy: prevalence and clinical features","volume":"16","author":"Mainieri","year":"2015","journal-title":"J Headache Pain"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10194-010-0191-6","article-title":"Comorbidity between headache and epilepsy in a pediatric headache center","volume":"11","author":"Toldo","year":"2010","journal-title":"J Headache Pain"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s10194-018-0940-5","article-title":"Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro","volume":"19","author":"Tringali","year":"2018","journal-title":"J Headache Pain"},{"key":"ref206","year":""},{"key":"ref207","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13543784.2017.1395411","article-title":"Glutamate receptor antagonists with the potential for migraine treatment","volume":"26","author":"Ferrari","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0333102413499648","article-title":"Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks","volume":"34","author":"Gomez-Mancilla","year":"2014","journal-title":"Cephalalgia"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"e7115","DOI":"10.7717\/peerj.7115","article-title":"Emerging trends and knowledge structure of epilepsy during pregnancy research for 2000-2018: a bibliometric analysis","volume":"7","author":"Wang","year":"2019","journal-title":"PeerJ"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2015.1017","article-title":"Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States","volume":"72","author":"MacDonald","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/epi.16821","article-title":"Perampanel and pregnancy","volume":"62","author":"Vazquez","year":"2021","journal-title":"Epilepsia"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"100490","DOI":"10.1016\/j.ebr.2021.100490","article-title":"Perampanel during pregnancy: description of four cases","volume":"16","author":"Alicino","year":"2021","journal-title":"Epilepsy Behav Rep"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.yebeh.2016.06.040","article-title":"Psychiatric comorbidities in epilepsy: should they be considered in the classification of epileptic disorders?","volume":"64","author":"Kanner","year":"2016","journal-title":"Epilepsy Behav"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(13)60899-5","article-title":"Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study","volume":"382","author":"Fazel","year":"2013","journal-title":"Lancet"},{"key":"ref218","doi-asserted-by":"publisher","first-page":"2064027","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"key":"ref219","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/epi.12504","article-title":"Adverse effects and safety profile of perampanel: a review of pooled data","volume":"55","author":"Rugg-Gunn","year":"2014","journal-title":"Epilepsia"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","article-title":"Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting","volume":"58","author":"Meschede","year":"2018","journal-title":"Seizure"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"106391","DOI":"10.1016\/j.yebeh.2019.06.034","article-title":"The impact of perampanel treatment on quality of life and psychiatric symptoms in patients with drug-resistant focal epilepsy: an observational study in Italy","volume":"99","author":"Deleo","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/cns.13098","article-title":"Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid","volume":"25","author":"Liguori","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"107515","DOI":"10.1016\/j.yebeh.2020.107515","article-title":"Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy","volume":"117","author":"Hasegawa","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200009073431007","article-title":"Treatment of acute ischemic stroke","volume":"343","author":"Brott","year":"2000","journal-title":"N Engl J Med"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0074-7742(08)60721-7","article-title":"Pharmacology of AMPA antagonists and their role in neuroprotection","volume":"40","author":"Gill","year":"1997","journal-title":"Int Rev Neurobiol"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejphar.2005.06.031","article-title":"The effects of AMPA receptor antagonists in models of stroke and neurodegeneration","volume":"519","author":"Gressens","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref227","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.brainres.2006.09.043","article-title":"Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats","volume":"1123","author":"Matucz","year":"2006","journal-title":"Brain Res"},{"key":"ref228","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.neuropharm.2007.12.007","article-title":"Neuroprotection for ischemic stroke: past, present and future","volume":"55","author":"Ginsberg","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref229","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4103\/1673-5374.255964","article-title":"Therapeutic potential of AMPA receptor antagonist perampanel against cerebral ischemia: beyond epileptic disorder","volume":"14","author":"Suda","year":"2019","journal-title":"Neural Regen Res"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"104848","DOI":"10.1016\/j.nbd.2020.104848","article-title":"Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition","volume":"140","author":"Mazzocchetti","year":"2020","journal-title":"Neurobiol Dis"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuroscience.2018.06.043","article-title":"AMPA receptor antagonist perampanel ameliorates post-stroke functional and cognitive impairments","volume":"386","author":"Nakajima","year":"2018","journal-title":"Neuroscience"},{"key":"ref232","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10571-017-0489-x","article-title":"The orally active noncompetitive AMPAR antagonist perampanel attenuates focal cerebral ischemia injury in rats","volume":"38","author":"Niu","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10571-015-0257-8","article-title":"The noncompetitive AMPAR antagonist perampanel abrogates brain endothelial cell permeability in response to ischemia: involvement of claudin-5","volume":"36","author":"Lv","year":"2016","journal-title":"Cell Mol Neurobiol"},{"key":"ref234","doi-asserted-by":"publisher","first-page":"e043488","DOI":"10.1136\/bmjopen-2020-043488","article-title":"Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke","volume":"11","author":"Nicolo","year":"2021","journal-title":"BMJ Open"},{"key":"ref235","year":""},{"key":"ref236","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","article-title":"Autism","volume":"383","author":"Lai","year":"2014","journal-title":"Lancet"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuroscience.2021.09.013","article-title":"The potential role of AMPA receptor trafficking in autism and other neurodevelopmental conditions","volume":"479","author":"Niescier","year":"2021","journal-title":"Neuroscience"},{"key":"ref238","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/epi.12378","article-title":"AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures","volume":"54","author":"Lippman-Bell","year":"2013","journal-title":"Epilepsia"},{"key":"ref239","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41386-018-0098-5","article-title":"Pharmacological modulation of AMPA receptor rescues social impairments in animal models of autism","volume":"44","author":"Kim","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref240","doi-asserted-by":"publisher","first-page":"106550","DOI":"10.1016\/j.eplepsyres.2021.106550","article-title":"Efficacy of perampanel in epilepsy patients with autism spectrum disorder","volume":"170","author":"Kanemura","year":"2021","journal-title":"Epilepsy Res"},{"key":"ref241","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/acn3.51030","article-title":"Abolishing spontaneous epileptiform activity in human brain tissue through AMPA receptor inhibition","volume":"7","author":"Wright","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref242","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2006.03.011","article-title":"A role for the mTOR pathway in surface expression of AMPA receptors","volume":"401","author":"Wang","year":"2006","journal-title":"Neurosci Lett"},{"key":"ref243","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1212\/wnl.56.7.906","article-title":"Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia","volume":"56","author":"Crino","year":"2001","journal-title":"Neurology"},{"key":"ref244","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/epi4.12549","article-title":"The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia","volume":"7","author":"Brito da Silva","year":"2022","journal-title":"Epilepsia Open"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1182304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T15:27:47Z","timestamp":1702740467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1182304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":244,"alternative-id":["10.3389\/fneur.2023.1182304"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1182304","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"article-number":"1182304"}}